HELIUS MEDICAL TECHNOLOGIE-A (HSDT) Stock Price, Quote, News and Overview
NASDAQ:HSDT - Nasdaq - US42328V8019 - Common Stock - Currency: USD
HSDT Quote, Performance and Key Statistics
NASDAQ:HSDT (5/30/2025, 3:06:01 PM)
3.95
+0.44 (+12.54%)
The current stock price of HSDT is 3.95 USD. In the past month the price decreased by -2.5%. In the past year, price decreased by -83.4%.
HSDT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.98 | 232.70B | ||
| ISRG | INTUITIVE SURGICAL INC | 72.35 | 198.11B | ||
| BSX | BOSTON SCIENTIFIC CORP | 38.89 | 155.36B | ||
| SYK | STRYKER CORP | 30.55 | 146.28B | ||
| MDT | MEDTRONIC PLC | 15.1 | 106.50B | ||
| BDX | BECTON DICKINSON AND CO | 12.3 | 49.66B | ||
| EW | EDWARDS LIFESCIENCES CORP | 30 | 45.75B | ||
| IDXX | IDEXX LABORATORIES INC | 45.07 | 41.64B | ||
| RMD | RESMED INC | 26.99 | 35.93B | ||
| DXCM | DEXCOM INC | 51.95 | 33.61B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.33 | 32.29B | ||
| STE | STERIS PLC | 26.25 | 24.09B |
Related stock screener links
About HSDT
Company Profile
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania and currently employs 21 full-time employees. The company went IPO on 2014-06-27. The firm is engaged in the medical device field focused on neurologic deficits using an orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS), is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy utilizes the PoNS device in conjunction with supervised therapeutic exercise. The PoNS Therapy consists of condition-specific exercises for movement control, including balance and gait training and breathing and awareness training, which are tailored to focus on the individual patient’s functional deficits.
Company Info
HELIUS MEDICAL TECHNOLOGIE-A
642 Newtown Yardley Road
Newtown PENNSYLVANIA 18940 US
CEO: Dane C. Andreeff
Employees: 21
Phone: 12159446100
HELIUS MEDICAL TECHNOLOGIE-A / HSDT FAQ
What is the stock price of HELIUS MEDICAL TECHNOLOGIE-A today?
The current stock price of HSDT is 3.95 USD. The price increased by 12.54% in the last trading session.
What is the ticker symbol for HELIUS MEDICAL TECHNOLOGIE-A stock?
The exchange symbol of HELIUS MEDICAL TECHNOLOGIE-A is HSDT and it is listed on the Nasdaq exchange.
On which exchange is HSDT stock listed?
HSDT stock is listed on the Nasdaq exchange.
What is HELIUS MEDICAL TECHNOLOGIE-A worth?
HELIUS MEDICAL TECHNOLOGIE-A (HSDT) has a market capitalization of 2.09M USD. This makes HSDT a Nano Cap stock.
How many employees does HELIUS MEDICAL TECHNOLOGIE-A have?
HELIUS MEDICAL TECHNOLOGIE-A (HSDT) currently has 21 employees.
What are the support and resistance levels for HELIUS MEDICAL TECHNOLOGIE-A (HSDT) stock?
HELIUS MEDICAL TECHNOLOGIE-A (HSDT) has a resistance level at 3.9. Check the full technical report for a detailed analysis of HSDT support and resistance levels.
Is HELIUS MEDICAL TECHNOLOGIE-A (HSDT) expected to grow?
The Revenue of HELIUS MEDICAL TECHNOLOGIE-A (HSDT) is expected to grow by 8.97% in the next year. Check the estimates tab for more information on the HSDT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HELIUS MEDICAL TECHNOLOGIE-A (HSDT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HSDT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HSDT, evaluating the profitability, health, valuation and growth aspects
- HELIUS MEDICAL TECHNOLOGIE-A (HSDT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HELIUS MEDICAL TECHNOLOGIE-A (HSDT) Sales and EPS estimates to see what analysts future expectations are.
- HELIUS MEDICAL TECHNOLOGIE-A (HSDT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HELIUS MEDICAL TECHNOLOGIE-A (HSDT) Insider and Institutional Ownership to learn about the owners and their transactions.
- HELIUS MEDICAL TECHNOLOGIE-A (HSDT) Stock Chart to make your own analysis
- HELIUS MEDICAL TECHNOLOGIE-A (HSDT) Latest news and press-releases to stay up to date.
Does HELIUS MEDICAL TECHNOLOGIE-A (HSDT) stock pay dividends?
HSDT does not pay a dividend.
When does HELIUS MEDICAL TECHNOLOGIE-A (HSDT) report earnings?
HELIUS MEDICAL TECHNOLOGIE-A (HSDT) will report earnings on 2025-08-11, after the market close.
What is the Price/Earnings (PE) ratio of HELIUS MEDICAL TECHNOLOGIE-A (HSDT)?
HELIUS MEDICAL TECHNOLOGIE-A (HSDT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-47.4).
HSDT Technical Analysis
HSDT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HSDT. HSDT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
HSDT Financial Highlights
Over the last trailing twelve months HSDT reported a non-GAAP Earnings per Share(EPS) of -47.4. The EPS increased by 75.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -374.97% | ||
| ROE | -1020.62% | ||
| Debt/Equity | 0 |
HSDT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to HSDT. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 88.61% and a revenue growth 8.97% for HSDT